drugset / Trial / NCT06559189
CD19x22 Chimeric Antigen Receptor T-cell Therapy (CAR T) in Pediatric B-ALL
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This study will evaluate the safety and tolerability of administering a novel bispecific CD19/CD22-directed CAR T cell product (CD19x22) for the treatment of relapsed or refractory pediatric B-ALL.
Timeline
- Start
- 2024-09-27
- Primary completion
- 2028-12
- Completion
- 2029-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CD19x22 CAR T | Cell therapy | 100000 cells/kg | — |
| Subject | CD19x22 CAR T | Cell therapy | 300000 cells/kg | — |